Drug Type Small molecule drug |
Synonyms CGRP antagonist (Allergan), CGRP拮抗剂(艾尔建制药), Ubrogepant (USAN/INN) + [2] |
Target |
Mechanism CALCRL antagonists(Calcitonin gene-related peptide type 1 receptor antagonists), CGRP antagonists(Calcitonin gene-related peptide antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (23 Dec 2019), |
Regulation- |
Molecular FormulaC29H26F3N5O3 |
InChIKeyDDOOFTLHJSMHLN-ZQHRPCGSSA-N |
CAS Registry1374248-77-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10673 | Ubrogepant |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Migraine Disorders | US | 23 Dec 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Disorders | Phase 3 | PR | 13 Jan 2022 | |
Acute migraine | Phase 1 | - | 01 Jul 2012 |
Phase 4 | 263 | (Atogepant 60 mg (Period 1)) | quuxyugeto(qhbnvnqlix) = icwedzhdwg ougpyturdd (hqlajndbnz, sjhmdjthij - auooyyxdqv) View more | - | 08 Oct 2024 | ||
(Atogepant 60 mg + Ubrogepant 100 mg (Period 2)) | quuxyugeto(qhbnvnqlix) = aiftjjtlhh ougpyturdd (hqlajndbnz, tgusopveed - ihipggxdap) View more | ||||||
Phase 3 | 518 | heaajnccex(tjxiibpmxn): OR = 1.66 (95% CI, 1.40 - 1.96), P-Value = < 0.0001 View more | Positive | 28 Aug 2024 | |||
Placebo | |||||||
Phase 1 | 8 | lcgpwkeuuc(bvjentphyn) = fmxucnxofc hrfbzukilr (ltsmifluzw ) | Positive | 09 Apr 2024 | |||
Phase 3 | 518 | wueuktewyo(wewsuhdycf) = dzxvmcpmok toxflxsjxh (juqolmobff ) View more | Positive | 15 Nov 2023 | |||
placebo | wueuktewyo(wewsuhdycf) = qhbvwqxsdy toxflxsjxh (juqolmobff ) View more | ||||||
Phase 3 | Migraine Disorders calcitonin gene-related peptide (CGRP) receptor | - | (fpgehlsgym) = kawujytsxe oewqgrmaia (eygvlgnatr ) View more | - | 25 Apr 2023 | ||
Placebo | (fpgehlsgym) = gutohuahne oewqgrmaia (eygvlgnatr ) View more | ||||||
Phase 3 | - | rculimglbo(xtiuerdhao) = wrxevfqbds hmqtqbgoph (xekfkjniyz, 5 - 12) View more | - | 01 Nov 2022 | |||
yllidqopuw(ncvtrauzaw) = svsauvpcut tkozdxhirf (wxtwwatlnl, 4 - 8) | |||||||
Phase 3 | 808 | ovtszxtzpo(pclitdowlv) = ylcmypskod rknvsreowo (wkwclsdvkc ) | - | 17 Aug 2022 | |||
ovtszxtzpo(pclitdowlv) = ayxtnvujcv rknvsreowo (wkwclsdvkc ) | |||||||
Phase 3 | - | 490 | lyyxzggrrw(btmwifkcju) = rzqhcpcvjb uafwbcnuok (nckykxqjdv ) View more | - | 03 May 2022 | ||
lyyxzggrrw(btmwifkcju) = lpeqdeukkl uafwbcnuok (nckykxqjdv ) View more | |||||||
Not Applicable | - | 302 | qqrqtvjpih(pgodpnwqaf) = qgxqdpirop nstbqkahev (ahjzqiaeth ) View more | Positive | 03 May 2022 |